PubMedCrossRef 5 Datta SR, Brunet A, Greenberg ME: Cellular surv

PubMedCrossRef 5. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905–2927.PubMedCrossRef 6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response see more to DNA damage. Cancer Res

1991, 51:6304–6311.PubMed 7. Mansur CP: The regulation and function of the p53 tumor suppressor. Adv Dermatol 1997, 13:121–166.PubMed 8. Sandor J, Ambrus T, Ember I: The function of the p53 gene suppressor in carcinogenesis. Orv Hetil 1995, 136:1875–1883.PubMed 9. Schoneich C: Protein modification in aging: an update. Exp Gerontol 2006, 41:807–812.PubMedCrossRef 10. Liu D, Xu Y: p53, oxidative stress, and aging. Antioxid Redox Signal 2011, 15:1669–1678.PubMedCentralPubMedCrossRef 11. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287:77–102.PubMed 12. Levy N, Yonish-Rouach E, Oren M, Kimchi A: Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 1993, 13:7942–7952.PubMedCentralPubMed www.selleckchem.com/products/i-bet151-gsk1210151a.html 13. Vennstrom B, Sheiness D,

Zabielski J, Bishop JM: Isolation and characterization of c-myc, a cellular homolog of the GSK2118436 supplier Oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 1982, 42:773–779.PubMedCentralPubMed 14. Pelengaris S, Khan M, Evan G: c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002, 2:764–776.PubMedCrossRef 15. Vita M, Henriksson M: The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006, 16:318–330.PubMedCrossRef heptaminol 16. Meyer N, Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976–990.PubMedCrossRef 17. Amati B, Alevizopoulos K, Vlach J: Myc and the cell cycle. Front Biosci 1998, 3:D250-D268.PubMed 18.

Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1–11.PubMedCentralPubMed 19. Eilers M: Control of cell proliferation by Myc family genes. Mol Cells 1999, 9:1–6.PubMed 20. Jung P, Hermeking H: The c-MYC-AP4-p21 cascade. Cell Cycle 2009, 8:982–989.PubMedCrossRef 21. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL: Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001, 98:4510–4515.PubMedCentralPubMedCrossRef 22. Müller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M: Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 1997, 15:2561–2576.PubMedCrossRef 23. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.PubMedCrossRef 24. Strasser A, Harris AW, Bath ML, Cory S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331–333.PubMedCrossRef 25.

Comments are closed.